Literature DB >> 7008588

Nosocomial infections in the immunocompromised adult.

L S Young.   

Abstract

It is universally accepted that the immunocompromised host is more susceptible to nosocomial infection than the normal host. Descriptive clinical or epidemiologic studies that utilize the "organism oriented" approach are now abundant. Generalizations about risk factors are difficult to make, however, because of the wide range of host defects that are usually compounded by therapeutic intervention. Comparative data are lacking on whether certain procedures or treatments are associated with a higher incidence of infection in immunocompromised hosts versus normal hosts. Aggressive diagnostic and therapeutic approaches to nosocomial infection in immunocompromised patients are usually advocated, but there have been few prospective studies of their effectiveness and the possible increased hazard of nosocomial infection. The paramount questions that must be addressed are, "What infections are preventable and how?" Two derivative issues relate to (1) the cost to benefit aspects of preventive measures, and (2) the impact of such measures on survival from underlying disease. Rigorously controlled studies of specific preventative measures are clearly required because the appearance of improvement may be related to concurrent improvements in the treatment of underlying disease or its complications. The ultimate value of infection control programs in immunocompromised patients with depend on the demonstration that intervention not only reduces infection rates but also has a favorable impact on the treatment of the underlying disease.

Entities:  

Mesh:

Year:  1981        PMID: 7008588     DOI: 10.1016/0002-9343(81)90779-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

Review 1.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Management of infection in the neutropenic patient.

Authors:  R E Marcus; J M Goldman
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-16

3.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

4.  Transplant infections--controversies about cost related issues.

Authors:  L S Young; M A Bermudez
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

5.  Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development.

Authors:  S J Cryz; P M Mortimer; V Mansfield; R Germanier
Journal:  J Clin Microbiol       Date:  1986-04       Impact factor: 5.948

6.  Purification and vaccine potential of Klebsiella capsular polysaccharides.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

7.  [Development of the risk of infection in the child with leukemia].

Authors:  P Lutz; G Delage; G E Rivard; G Berdnikoff
Journal:  Can Med Assoc J       Date:  1983-09-01       Impact factor: 8.262

8.  Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats.

Authors:  P Longuet; V Joly; P Amirault; N Seta; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R L Hopfer; R Mehta; K Mehta; E M Hersh; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

10.  Comparative in vitro activity of cefpirome (HR 810) against gram-positive isolates from cancer patients.

Authors:  K V Rolston; G P Bodey
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.